Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Neurochemical dementia diagnostics: assays in CSF and blood.

Literature DB >> 18985294

Neurochemical dementia diagnostics: assays in CSF and blood.

Piotr Lewczuk¹, Joachim Hornegger, Rüdiger Zimmermann, Markus Otto, Jens Wiltfang, Johannes Kornhuber.

Abstract

In this review, current neurochemical dementia diagnostics (NDD) procedures are presented with a focus on biomarkers in the cerebrospinal fluid (CSF) and blood: amyloid beta peptides, tau protein, and its phosphorylated form (pTau). CSF analysis is an increasingly important tool for early and differential diagnosis of dementia syndromes. Although lumbar puncture is a mildly invasive procedure with a low incidence of complications, establishing blood assays capable of reliably measuring NDD biomarkers is an aim of several studies worldwide.

Entities: Chemical Disease

Mesh：

Substances：

Year: 2008 PMID： 18985294 DOI： 10.1007/s00406-008-5005-3

Source DB: PubMed Journal: Eur Arch Psychiatry Clin Neurosci ISSN： 0940-1334 Impact factor: 5.270

58 in total

1. The intramembrane cleavage site of the amyloid precursor protein depends on the length of its transmembrane domain.

Authors: Stefan F Lichtenthaler; Dirk Beher; Heike S Grimm; Rong Wang; Mark S Shearman; Colin L Masters; Konrad Beyreuther
Journal: Proc Natl Acad Sci U S A Date: 2002-01-22 Impact factor: 11.205

2. Reduced CSF carboxyterminally truncated Abeta peptides in frontotemporal lobe degenerations.

Authors: M Bibl; B Mollenhauer; S Wolf; H Esselmann; P Lewczuk; J Kornhuber; J Wiltfang
Journal: J Neural Transm (Vienna) Date: 2007-01-25 Impact factor: 3.575

3. CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group.

Authors: L Parnetti; A Lanari; S Amici; V Gallai; E Vanmechelen; F Hulstaert
Journal: Neurol Sci Date: 2001-02 Impact factor: 3.307

4. Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease.

Authors: M Otto; H Esselmann; W Schulz-Shaeffer; M Neumann; A Schröter; P Ratzka; L Cepek; I Zerr; P Steinacker; O Windl; J Kornhuber; H A Kretzschmar; S Poser; J Wiltfang
Journal: Neurology Date: 2000-03-14 Impact factor: 9.910

5. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias.

Authors: M Bibl; B Mollenhauer; P Lewczuk; H Esselmann; S Wolf; C Trenkwalder; M Otto; G Stiens; E Rüther; J Kornhuber; J Wiltfang
Journal: Mol Psychiatry Date: 2007-03-06 Impact factor: 15.992

6. Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities.

Authors: M Citron; T S Diehl; G Gordon; A L Biere; P Seubert; D J Selkoe
Journal: Proc Natl Acad Sci U S A Date: 1996-11-12 Impact factor: 11.205

Review 7. Signal transduction during amyloid-beta-peptide neurotoxicity: role in Alzheimer disease.

Authors: Rodrigo A Fuentealba; Ginny Farias; Jessica Scheu; Miguel Bronfman; María Paz Marzolo; Nibaldo C Inestrosa
Journal: Brain Res Brain Res Rev Date: 2004-12

8. Differential level of platelet amyloid beta precursor protein isoforms: an early marker for Alzheimer disease.

Authors: M Di Luca; L Pastorino; A Bianchetti; J Perez; L A Vignolo; G L Lenzi; M Trabucchi; F Cattabeni; A Padovani
Journal: Arch Neurol Date: 1998-09

Review 9. Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases.

Authors: Markus Otto; Piotr Lewczuk; Jens Wiltfang
Journal: Methods Date: 2008-04 Impact factor: 3.608

10. Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease: original data and review of the literature.

Authors: Piotr Lewczuk; Hermann Esselmann; Mirko Bibl; Georg Beck; Juan Manuel Maler; Markus Otto; Johannes Kornhuber; Jens Wiltfang
Journal: J Mol Neurosci Date: 2004 Impact factor: 2.866

5 in total

1. A visual [18F]FDG-PET rating scale for the differential diagnosis of frontotemporal lobar degeneration.

Authors: Stefan Poljansky; Bernd Ibach; Barbara Hirschberger; Peter Männer; Hans Klünemann; Göran Hajak; Jörg Marienhagen
Journal: Eur Arch Psychiatry Clin Neurosci Date: 2011-01-05 Impact factor: 5.270

2. Quantitative proteomics and metabolomics analysis of normal human cerebrospinal fluid samples.

Authors: Marcel P Stoop; Leon Coulier; Therese Rosenling; Shanna Shi; Agnieszka M Smolinska; Lutgarde Buydens; Kirsten Ampt; Christoph Stingl; Adrie Dane; Bas Muilwijk; Ronald L Luitwieler; Peter A E Sillevis Smitt; Rogier Q Hintzen; Rainer Bischoff; Sybren S Wijmenga; Thomas Hankemeier; Alain J van Gool; Theo M Luider
Journal: Mol Cell Proteomics Date: 2010-09 Impact factor: 5.911

Review 3. New developments in the diagnosis of dementia.

Authors: Gerhard W Eschweiler; Thomas Leyhe; Stefan Klöppel; Michael Hüll
Journal: Dtsch Arztebl Int Date: 2010-10-01 Impact factor: 5.594

4. A proteomic approach for the diagnosis of bacterial meningitis.

Authors: Sarah Jesse; Petra Steinacker; Stefan Lehnert; Martin Sdzuj; Lukas Cepek; Hayrettin Tumani; Olaf Jahn; Holger Schmidt; Markus Otto
Journal: PLoS One Date: 2010-04-08 Impact factor: 3.240

5. GC/MS-based metabolomic analysis of cerebrospinal fluid (CSF) from glioma patients.

Authors: Satoshi Nakamizo; Takashi Sasayama; Masakazu Shinohara; Yasuhiro Irino; Shin Nishiumi; Masamitsu Nishihara; Hirotomo Tanaka; Kazuhiro Tanaka; Katsu Mizukawa; Tomoo Itoh; Masaaki Taniguchi; Kohkichi Hosoda; Masaru Yoshida; Eiji Kohmura
Journal: J Neurooncol Date: 2013-03-01 Impact factor: 4.130

5 in total